Shots:
- Neumora has received a $100M as an equity investment and obtains an exclusive global right to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases
- The collaboration will utilize Neumora’s precision neuroscience platform with Amgen’s deCODE human genetics capabilities to boost innovative therapies for the treatment of brain disease
- Neumora’s precision neuroscience platform focuses on the Data Biopsy Signatures to develop the complex systems for brain diseases & develop therapies for an enriched patient population or Precision Phenotypes
Click here to read full press release/ article | Ref: PR Newswire | Image: Biospace
The post Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases first appeared on PharmaShots.
